TipRanks
Advertisement
Advertisement

SANA Stock Latest News

Sana Biotechnology Faces Investor Lawsuit as Court Weighs Motion to Dismiss Securities Claims Over ARDENT Trial Disclosures 
Class ActionSana Biotechnology Faces Investor Lawsuit as Court Weighs Motion to Dismiss Securities Claims Over ARDENT Trial Disclosures 
6d ago
SANA
Sana Biotechnology Highlights Progress in Diabetes and Oncology Therapies
PremiumCompany Announcements
Sana Biotechnology Highlights Progress in Diabetes and Oncology Therapies
14d ago
8K
SANA
Sana Biotechnology price target lowered to $6 from $7 at BofA
PremiumThe Fly
Sana Biotechnology price target lowered to $6 from $7 at BofA
1M ago
SANA
Sana Biotechnology reports Q2 EPS (13c), consensus (12c)
PremiumThe Fly
Sana Biotechnology reports Q2 EPS (13c), consensus (12c)
1M ago
SANA
Sana Biotechnology announces publication of long-term diabetes data
PremiumThe Fly
Sana Biotechnology announces publication of long-term diabetes data
2M ago
SANA
Sana Biotechnology Shareholders Reelect Directors and Ratify Auditor
PremiumCompany AnnouncementsSana Biotechnology Shareholders Reelect Directors and Ratify Auditor
4M ago
8K
SANA
Sana Biotechnology Raises $69 Million Through Equity Offering
Premium
Company Announcements
Sana Biotechnology Raises $69 Million Through Equity Offering
4M ago
8K
SANA
Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy
Premium
The Fly
Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy
4M ago
SANA
Sana Biotechnologies: Mayo Collaboration and HIP Platform Progress Reinforce Buy Rating and Unchanged $7 Price Target
PremiumRatings
Sana Biotechnologies: Mayo Collaboration and HIP Platform Progress Reinforce Buy Rating and Unchanged $7 Price Target
4M ago
SANA
Frahm Initiates Buy on Sana Biotechnology, Citing Differentiated In Vivo CAR‑T Pipeline and Strong Cash Runway into 2027
PremiumRatings
Frahm Initiates Buy on Sana Biotechnology, Citing Differentiated In Vivo CAR‑T Pipeline and Strong Cash Runway into 2027
4M ago
SANA
Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)
PremiumThe Fly
Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)
4M ago
SANA
Sana Biotechnology initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Sana Biotechnology initiated with a Buy at Rodman & Renshaw
4M ago
SANA
SANA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsSANA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
SANA
Sana Biotechnology options imply 5.3% move in share price post-earnings
Premium
The Fly
Sana Biotechnology options imply 5.3% move in share price post-earnings
5M ago
SANA
Sana Biotechnology Rebalances Board Classes With Director Shift
Premium
Company Announcements
Sana Biotechnology Rebalances Board Classes With Director Shift
5M ago
8K
SANA
Sana Biotechnology price target raised to $7 from $6 at Wedbush
PremiumThe Fly
Sana Biotechnology price target raised to $7 from $6 at Wedbush
5M ago
SANA
Sana Biotechnology: Mayo Clinic Collaboration and UP421 Data De‑Risk SC451 and Support Buy Rating on Type 1 Diabetes Momentum
PremiumRatings
Sana Biotechnology: Mayo Clinic Collaboration and UP421 Data De‑Risk SC451 and Support Buy Rating on Type 1 Diabetes Momentum
5M ago
SANA
Sana Biotechnology Secures Strategic Equity Investment from Mayo
PremiumCompany Announcements
Sana Biotechnology Secures Strategic Equity Investment from Mayo
5M ago
8K
SANA
Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic
PremiumThe Fly
Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic
5M ago
SANA
Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating
PremiumRatingsDurable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating
6M ago
SANA
Sana announces follow-up results from first-in-human study transplanting UP421
Premium
The Fly
Sana announces follow-up results from first-in-human study transplanting UP421
6M ago
SANA
Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating
Premium
Ratings
Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating
7M ago
SANA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >